Dr Sara Nunez-Garcia
Sara Núñez-García is a Senior Associate at Sofinnova Partners, a life sciences venture capital fund based in Paris, France. She joined in January 2013 and she focuses on investments in the biotech and medical device sectors. She is actively involved in the scouting and due diligence of new investment opportunities and supports several portfolio companies. In addition, she serves as an expert for the NIH review committee for SMEs.
Prior to Sofinnova Partners, Sara worked in the Licensing and M&A team at Onyx Pharmaceuticals (now Amgen) in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space.
Previously, Sara spent six years in the pharmaceutical industry with Solvay and Abbott Laboratories (now Abbvie) in The Netherlands as a Medicinal Chemist. During her time in drug discovery, Sara worked on preclinical programmes for central nervous system indications, contributing to the submission of several IND packages of novel chemical entities. In addition, Sara led transfer-of-knowledge projects with several universities in Amsterdam.
Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed inhibitors for oncology targets.
She also has a PhD in Chemistry from the University of Manchester; her doctoral research used a combination of experimental and computational techniques to design and synthesize transition state inhibitors. Sara has published eighteen peer-reviewed articles and patents.
In addition, Sara also holds an MBA from INSEAD, with a focus on finance.